Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
KRYSTEXXA: PROTECT Trial Designed to Support Nephrologists' Understanding of Efficacy
Evaluating KRYSTEXXA to Improve Management of Uncontrolled Gout in Kidney Transplant Patients
Gout is 10 times more
frequent in kidney
transplant patients
⚫ PROTECT is designed to
provide data for most
severe chronic kidney
disease patients
PROTECT Trial Design
20 Kidney Transplant Patients with Uncontrolled Gout Evaluated for 24 Weeks
KRYSTEXXA (n=20)
12 infusions: 1 every two weeks
Day 1
Week 24
Initiated Q3 2019; Data Readout Expected in 2021
Primary Endpoint
Primary Endpoint at Week 24:
Proportion of serum uric acid (SUA) responders (SUA <6 mg/dL) at Month 6
PROTECT: Clinical trial evaluating the effect of KRYSTEXXA on serum uric acid levels in kidney transplant patients with uncontrolled gout.
HORIZON
30View entire presentation